This report evaluates the clinical utility of pharmacogenomic testing to inform the selection or dose of medications for individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD) to improve clinical outcomes.
If you have a Hayes login, click here to view the full report on the Knowledge Center.